Mark Wayne Ball, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD, discusses the unmet needs to surgery for kidney cancer, particularly in patients with poor-risk disease. As exemplified by the Phase III CARMENA (NCT00930033) trial, patients who are poor-risk do not benefit from upfront surgery, as well as other treatment modalities, thus a major unmet need is uncovering an effective treatment for this patient population. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
